Hangzhou, August 27, 2024 / PRNewswire / - Wo Ke Medical Technology Group Co., Ltd. (NASDAQ stock code: WOK) (hereinafter referred to as 'the Company'), a Chinese medical device supplier, announced today that it has completed its initial public offering pricing, issuing 2,000,000 common shares at a price of $4.00 per share. The Company's common shares began trading on NASDAQ on August 23, 2024, Eastern Time, under the stock code 'WOK'.
Before deducting underwriting discounts and related offering expenses, the Company expects to raise a total of 8 million dollars in this offering. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 300,000 common shares at the public offering price (less underwriting discount commissions).
The proceeds from this offering will be used for (1) upgrading production equipment and increasing production capacity; (2) developing masks, other medical consumables, and medical device equipment; (3) product marketing; (4) purchasing patents; and (5) operational capital and other general corporate purposes.
This offering is conducted on a firm-commitment basis. Kingswood Capital Partners, LLC (hereinafter referred to as 'Kingswood') serves as the exclusive bookrunner for this offering. Hunter Taubman Fischer & Li LLC acts as legal counsel for the issuer, and Ortoli Rosenstadt LLP acts as legal counsel for Kingswood.
The application registration form for this issuance (Filing No: 333-271474) has been submitted to the U.S. Securities and Exchange Commission ("SEC"), and was declared effective by the SEC on August 22, 2024. This issuance is only conducted through a prospectus. Copies of the final prospectus for the issuance can be obtained by contacting Kingswood at 7280 W Palmetto Park Rd. Suite 301, Boca Raton, FL 33433, or by emailing lciervo@kingswoodus.com, or by calling +1-800-535-6981. In addition, electronic copies of the prospectus for the issuance can also be obtained through the SEC website (www.sec.gov).
This press release does not constitute a sales invitation or an invitation to purchase; making such offers, invitations, or sales before registration or qualification under the securities laws of any state or jurisdiction is illegal and cannot be made in these states or jurisdictions for the sale of such securities.
About Voco Medical Technology Group Limited
Voco Medical Technology Group Limited is a medical device supplier, developing and producing Class I and Class II medical devices through its operating subsidiaries in China, and selling Class I and Class II disposable medical devices. The company has a diverse product portfolio, including custom and multi-functional masks and other medical consumables, totaling 21 products. All products have been sold in 34 provincial-level administrative regions in China, with 15 products exported to more than 30 countries globally. The company has obtained several manufacturing certifications related to quality and has registered 17 products with the U.S. Food and Drug Administration for entry into the U.S. market. For more information, please visit the company's website.
Forward-looking statements
This press release contains forward-looking statements, including statements made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified as forward-looking statements by words such as "target," "expect," "believe," "may," "estimate," "expect," "forecast," "target," "intend," "can," "plan," "possible," "potential," "seek," "will" and similar expressions or variations of such words. Any non-historical statements in this press release may be deemed forward-looking statements.
Any forward-looking statements in this press release are based only on the company's current expectations, estimates, and forecasts as of the date of this press release and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in these forward-looking statements. While the company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot guarantee that these expectations will prove to be correct, and the company cautions investors that actual results may differ materially from those expected results and recommends that investors review other factors that may affect the company's future results as listed in the company's registration statement on Form F-1 and other documents submitted to the U.S. Securities and Exchange Commission. The company expressly disclaims any obligation to update any forward-looking statements, except as required by law.
For more information, please contact:
Voke Medical Technology Group Limited
Investor Relations Department
Email: ir@workmedtech.com
Ascent Investor Relations Company, Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com